Penflutizide ‎is a thiazide diuretic drug, Na+-Cl- symport inhibitor. Penflutizide was shown to have high potency to photooxidize lipids. Penflutizide -photosensitized peroxidation of squalene was repressed by the presence of sodium azide or 2,5-dimethylfuran and was accelerated in a D2O suspension. These findings suggest the participation of singlet oxygen in Penflutizide photoperoxidation of squalene (type II mechanism). Penflutizide -photosensitized lysis of red blood cells (RBC) accompanied by formation of hydroperoxides in RBC membrane lipids was also noted. These results suggested that membrane lipids can be one of the target molecules of Penflutizide phototoxicity. Penflutizide ‎is an ingredient of the drug Praemenstron manufactured by Nordmark Arzneimittel and consisting of Flumedroxone, Meprobamate, Penflutizide.

Clorindione belongs to a class of drugs which are known to be vitamin K antagonists, and is a derivative of phenindione. It has been demonstrated as effective in reducing prothrombin levels in humans and also to reduce serum cholesterol and triglycerides in mice.

Mebutizide is a medium strength antihypertensive diuretic (similar to hydrochlorothiazide and altizide).

Israpafant (also known as Y-24180) is a drug which acts as a selective antagonist for the platelet-activating factor receptor, and was originally developed for the treatment of asthma. Its chemical structure is a thienotriazolodiazepines, closely related to the sedative benzodiazepine derivative etizolam. However, israpafant binds far more tightly to the platelet-activating factor receptor, with an IC50 of 0.84nM for inhibiting PAF-induced human platelet aggregation, while it binds only weakly to benzodiazepine receptors, with a Ki of 3680nM. Israpafant has been found to inhibit the activation of eosinophil cells and consequently delays the development of immune responses. It has also been shown to have anti-nephrotoxic properties and to mobilize calcium transport.

Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would withdraw pending applications for marketing approval after reports of hepatotoxicity (liver damage) during trials, and discontinue its distribution in countries where the drug had been approved (Germany, Portugal, Sweden, Finland, Norway, Iceland, Austria, Denmark, France, Switzerland, Argentina and Brazil). Ximelagatran is a prodrug that is rapidly converted after oral administration to the active compound melagatran. Melagatran is able to inhibit thrombin activity directly and quickly. The melagatran molecule binds to the arginine side pocket of thrombin, inactivating the thrombin. Following oral administration of ximelagatran, oral bioavailability (measured as melagatran) is 18% to 25%. Peak melagatran levels after a ximelagatran dose of 48 mg twice daily are achieved within approximately 2 hours. Ximelagatran is rapidly and extensively converted to melagatran in the liver and other tissues. This conversion is achieved by ester hydrolysis and reduction via two intermediate metabolites, hydroxymelagatran, and ethylmelagatran. The predominant compound in plasma is the active drug, melagatran. The elimination half-life of melagatran after an oral dose of ximelagatran is 2.5 to 4.3 hours.

Cloricromen a drug that inhibits platelet aggregation in man and in experimental thrombosis. Experiments on rodents have revealed that cloricromene which reduced tumor necrosis factor production, could be useful in the treatment of periodontitis. In addition, it could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable. However, experiments with patients with cerebrovascular occlusive disease didn’t shown any effect of cloricromen on coagulative variables.

Etozolin is a diuretic used in Europe under the names Diulozin, Elkapin, Etopinil for the treatment of edema and hypertension. The exact mechanism of etozolin action is unknown. The current marketing status of the drug is unavailable and is supposed to be discontinued.

Paraflutizide is a thiazide diuretic, which is used in the treatment of hypertension.

Ditazole, a non-steroidal anti-inflammatory drug with anti-aggregation activity, is marketed under the brand name Ageroplas in Spain and Portugal. Ageroplas is indicated for the prophylaxis and treatment of thrombotic vasculopathy or thromboembolic arteriosclerosis, hypertension, diabetes mellitus, vascular nephropathy, and glomerular, cardiac and vascular prostheses, phlebitis and thrombophlebitis. Ditazole also possesses analgesic and antipyretic activity.

Cyclopenthiazide is a thiazide diuretic. It inhibits the Na+-Cl− symporter in the distal convoluted tubule of the kidney. Cyclopenthiazide is used for the treatment of edema, including that associated with heart failure, and for the treatment of hypertension.